R744 + Epoetin beta
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Predialysis Patients
Conditions
Predialysis Patients
Trial Timeline
Jun 1, 2007 → Nov 1, 2008
NCT ID
NCT00492427About R744 + Epoetin beta
R744 + Epoetin beta is a phase 3 stage product being developed by Chugai Pharmaceutical for Predialysis Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT00492427. Target conditions include Predialysis Patients.
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00492427 | Phase 3 | Completed |